

Ceftriaxone Market Poised for Steady Growth Through 2031, Surpassing USD 2.2 Billion in Value | TMR Study

Increase in incidence of urinary tract infection and rise in awareness about bacterial infection

WILMINGTON, DELAWARE, UNITED STATES, October 25, 2023 /EINPresswire.com/ -- Ceftriaxone Market was valued at USD 1.7 billion in 2021. Driven by rising antibiotic prescriptions and increasing prevalence of infectious diseases, the market has experienced steady growth over the past decade. According to a recent report, the ceftriaxone market is projected to continue this momentum, expanding at a compound annual growth rate (CAGR) of 2.9% from 2022 to 2031. By the end of 2031, the total market size is expected to surpass USD 2.2 billion.



000000 0000000:

Growing prevalence of infectious diseases such as pneumonia, skin infections, urinary tract infections, etc. which require treatment with ceftriaxone.

Increasing healthcare expenditure and access to healthcare in developing countries.

Rising geriatric population who are more susceptible to bacterial infections.

New product launches with improved formulations and delivery methods. Patent expiries of major drugs leading to cheaper generic competition. Stringent regulations for drug approval. Development of antibiotic resistance reducing effectiveness of drugs like ceftriaxone. Focus on developing novel drug delivery systems like liposomes, nanoparticles to improve efficacy. Combination therapies with ceftriaxone to treat multi-drug resistant infections. Growth in demand for generic versions due to lower costs. Shift towards large volume parenteral drugs in developing countries. Types, applications, regions, and key players covered in the study Industry drivers, restraints, and opportunities covered in the study Recent industry trends and developments Competitive landscape & strategies of key players Historical, current, and projected market size, in terms of value

In-depth analysis of the Ceftriaxone Market

Sales, price, revenue, market share, and growth rate are covered in the report sales channels, distributors, traders, dealers, etc. are covered in the report

https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=85274

Urinary Tract Infections
Intra-abdominal Infections
Endocarditis
Acute Bacterial Otitis Media
Meningitis
Pneumonia
Others
0000000000000000000
Hospital Pharmacies
Retail Pharmacies
Online Pharmacies
00000000 0000000
Hikma Pharmaceuticals plc
Qilu Pharmaceutical Co. Ltd.
Novartis AG
Baxter International, Inc.
Aurobindo Pharma
ACS DOBFAR S.P.A.
Orchid Pharma
Nectar Lifesciences Ltd.
Lupin Pharmaceuticals, Inc.

North America (United States, Canada and Mexico)

Europe (Germany, UK, France, Italy, Russia and Spain etc.)

Asia-Pacific (China, Japan, Korea, India, Australia and Southeast Asia etc.)

South America (Brazil, Argentina and Colombia etc.)

Middle East & Africa (South Africa, UAE and Saudi Arabia etc.)

0000 000 00000? 000 000 0000000

https://www.transparencymarketresearch.com/sample/sample.php?flag=ASK&rep_id=85274

Identify the latest developments, market shares and strategies employed by the major market players.

Analysing various perspectives of the market with the help of Porter's five forces analysis

Study on the product type and application expected to dominate the market.

Study on the country expected to witness fastest growth during the forecast period.

Forecasts the market value by assessing the impact of the market drivers and constraints.

Amyotrophic Lateral Sclerosis Treatment Market

Increased consumer and medical professional knowledge regarding novel treatments is predicted to drive growth in the global amyotrophic lateral sclerosis (ALS) treatment market. The introduction of stem cell therapy as a novel therapeutic option for ALS is expected to boost market growth.

Cancer Profiling Market

Growth in preference for personalized medicine is expected to create lucrative opportunities for Cancer Profiling Market players during the forecast period

Nikhil Sawlani
Transparency Market Research Inc.
+1 518-618-1030
email us here
Visit us on social media:
Twitter
LinkedIn
YouTube

This press release can be viewed online at: https://www.einpresswire.com/article/664139467

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information. © 1995-2023 Newsmatics Inc. All Right Reserved.